Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4, with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedLocations now include Louisville, Kentucky, indicating an added study site. The HHS Vulnerability Disclosure link in the footer has been removed.SummaryDifference0.2%

- Check48 days agoChange DetectedRevision: v3.3.2 appears at the top of the page, replacing v3.3.1; there are no changes to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedMinor wording edits in the Publications section (the sentence about publications now states 'These publications are provided voluntarily by the person who enters information about the study and are about the results of the study.') and an update to the page revision tag (Revision: v3.3.1); no substantive study information is affected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedA government funding status notice was removed from the page. The core study details, eligibility criteria, and contact information remain unchanged.SummaryDifference0.4%

- Check76 days agoChange DetectedNo additions or deletions detected on the page; the content appears unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.